Form 4: LifeCore Biomedical CEO Paul Josephs Acquires 17,000 Shares
SEC Form 4 Filing
LifeCore Biomedical's CEO, Paul Josephs, purchased 17,000 shares of common stock at $5.74 per share on January 8, 2025.
Summary
- On January 8, 2025, Paul Josephs, the CEO of LifeCore Biomedical, Inc., acquired 17,000 shares of the company's common stock.
- The purchase price was $5.74 per share.
- Following this transaction, Josephs directly owns 559,717 shares of LifeCore Biomedical.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO's purchase is a positive signal, but it's a routine transaction disclosure.
Positives
- The CEO's purchase of company stock may signal confidence in the company's future prospects.
Industry Context
Insider buying is often seen as a positive sign, suggesting that a company's management believes the stock is undervalued. However, it's just one factor to consider when evaluating a company's potential.
Stakeholder Impact
- The CEO's stock purchase could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 01/08/2025 | Date of stock acquisition by Paul Josephs |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.